Monaco Asset Management SAM Increases Stock Holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR)

Key Points

• Monaco Asset Management SAM increased its holdings in ProQR Therapeutics by 59.1%, acquiring an additional 175,290 shares, bringing their total to 471,908 shares valued at approximately $628,000.
• Other hedge funds, including Adage Capital Partners and Millennium Management LLC, also significantly increased their stakes in ProQR Therapeutics during the fourth quarter, showcasing increasing institutional interest in the company.
• ProQR Therapeutics reported a loss of ($0.11) EPS in its latest quarterly earnings, falling short of expectations, with anticipated earnings for the year projected at ($0.31) EPS.

Monaco Asset Management SAM increased its holdings in shares of ProQR Therapeutics N.V. (NASDAQ:PRQR - Free Report) by 59.1% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 471,908 shares of the biopharmaceutical company's stock after purchasing an additional 175,290 shares during the quarter. Monaco Asset Management SAM owned approximately 0.45% of ProQR Therapeutics worth $628,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in PRQR. Raymond James Financial Inc. purchased a new position in shares of ProQR Therapeutics during the fourth quarter valued at about $260,000. Virtu Financial LLC purchased a new position in ProQR Therapeutics in the fourth quarter worth about $83,000. American Century Companies Inc. purchased a new position in ProQR Therapeutics in the fourth quarter worth about $237,000. Prudential Financial Inc. grew its position in ProQR Therapeutics by 109.1% in the fourth quarter. Prudential Financial Inc. now owns 27,600 shares of the biopharmaceutical company's stock worth $73,000 after acquiring an additional 14,400 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in ProQR Therapeutics by 17,707.7% in the fourth quarter. JPMorgan Chase & Co. now owns 53,423 shares of the biopharmaceutical company's stock worth $142,000 after acquiring an additional 53,123 shares in the last quarter. Hedge funds and other institutional investors own 32.65% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on PRQR. Oppenheimer dropped their price target on ProQR Therapeutics from $15.00 to $9.00 and set an "outperform" rating for the company in a research report on Tuesday, May 13th. Cantor Fitzgerald reissued an "overweight" rating and set a $8.00 price target on shares of ProQR Therapeutics in a research note on Friday, June 27th. Evercore ISI reissued an "outperform" rating on shares of ProQR Therapeutics in a research note on Friday, July 11th. Finally, JMP Securities reissued a "market outperform" rating and set a $8.00 price target on shares of ProQR Therapeutics in a research note on Friday, June 27th. One research analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, ProQR Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $8.00.

ProQR Therapeutics Stock Performance

NASDAQ PRQR traded down $0.02 on Friday, reaching $2.08. 139,878 shares of the stock traded hands, compared to its average volume of 209,588. The company has a fifty day moving average price of $2.05 and a 200-day moving average price of $1.89. The company has a market cap of $218.84 million, a price-to-earnings ratio of -5.94 and a beta of 0.43. ProQR Therapeutics N.V. has a 12 month low of $1.07 and a 12 month high of $4.62.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). The firm had revenue of $4.89 million for the quarter, compared to the consensus estimate of $4.90 million. ProQR Therapeutics had a negative net margin of 157.04% and a negative return on equity of 53.49%. As a group, research analysts anticipate that ProQR Therapeutics N.V. will post -0.31 earnings per share for the current fiscal year.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).